More De-Risking Required Before Pharma Dives Into Psychedelics

Pharmaceutical companies are steering clear of psychedelics at present but their potential to treat conditions with high unmet medical needs including depression, substance use and pain means that the big players are keeping a close eye on the space.

That was one of the key messages to come out of a panel at BIO International Convention in San Diego last week entitled Psychedelics: What Will It Take To Get Them to Market? Kurt Rasmussen, chief scientific officer at Delix Therapeutics, Inc